Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134411 | 0.87 | LMNA (0.56) | LMNAHTTGPR55ADORA1ADORA2A | |
| SCHEMBL6133777 | 0.87 | ADORA1 (0.41) | LMNAADORA1ADORA2AKMT2AMEN1 | |
| SCHEMBL6133302 | 0.87 | CYP1A2 (0.54) | ADORA1ADORA2AKMT2A | |
| SCHEMBL6133477 | 0.86 | ADORA1 (0.55) | LMNAADORA1ADORA2AKMT2AMEN1 | |
| SCHEMBL6133973 | 0.86 | ADORA1 (0.55) | LMNAADORA1ADORA2AKMT2AMEN1 | |
| SCHEMBL6134045 | 0.84 | RPS6KA3 (0.44) | LMNAADORA1ADORA2AKMT2AMEN1 | |
| SCHEMBL6133724 | 0.84 | KMT2A (0.64) | LMNAHTTADORA1ADORA2AKMT2A | |
| SCHEMBL6133920 | 0.81 | ADORA1 (0.42) | LMNAADORA1ADORA2AKMT2AMEN1 | |
| SCHEMBL6133893 | 0.81 | FGFR1 (0.43) | ADORA1ADORA2A | |
| SCHEMBL6133937 | 0.80 | ADORA2A (0.39) | LMNAADORA1ADORA2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | LMNA 3549/4885HTT 184/4885GPR55 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.